TITLE

BIOLINERX IN-LICENSES NOVEL DRUG FOR ACUTE KIDNEY INJURY

PUB. DATE
October 2007
SOURCE
Worldwide Biotech;Oct2007, Vol. 19 Issue 10, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the license agreement signed by BioLineRx Ltd. with Gene Vector Technologies Ltd. for the development and commercialization of BL-4040, a novel drug for the treatment of acute kidney injury. The said drug is a genetically-engineered version of the major capsid protein VP1 derived from the outer protein shell of the virus SV40. Research found that the drug was effective for the treatment of AKI over a wide dose range and was well-tolerated even at a 1,000 fold excess dose.
ACCESSION #
26715140

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics